Antiepileptic drugs and bone
Not Applicable
Completed
- Conditions
- Health Condition 1: null- All females of age â?º 20-65 years, diagnosed with epilepsy. Patients receiving sodium valproate, carbamazepine or levetiracetam as monotherapy for atleast a year.
- Registration Number
- CTRI/2018/02/012232
- Lead Sponsor
- Department of Science and Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 66
Inclusion Criteria
Patients receiving sodium valproate, carbamazepine or levetiracetam as monotherapy for atleast a year.
Exclusion Criteria
Women with conditions known to affect bone and mineral metabolism (such as primary hyperparathyroidism, Pagetâ??s disease, multiple myeloma, hepatic or renal disorders, diabetes mellitus, thyroid diseases, malignancy or malabsorption)
Women taking glucocorticoids that are known to affect bone and mineral metabolism.
Patients in which sodium valproate, carbamazepine and levetiracetam are prescribed for condition other than epilepsy.
Patients with smoking habit.
Patients who refuse to give consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method